MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-RJ-17-0167681
Asle Pharmaceuticals Private Limited
Asle Pharmaceuticals Private Limited - pharma in Jaipur, Rajasthan, India. Directors, charges & compliance details.
Revenue · FY 2025
₹25.9 Cr
▲ 7% YoY
Net profit · FY 2025
₹1.62 Cr
Net margin 6.2%
EBITDA · FY 2025
₹2.33 Cr
EBITDA margin 9%
Authorised capital
₹10 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Company age
4 yrs
Est. 2022
Directors on board
3
As per MCA filings
Active GSTINs
1
GST registered
About Asle Pharmaceuticals Private Limited
Data last updated:
Asle Pharmaceuticals Private Limited is a private limited company based in Jaipur, Rajasthan, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 April 2022.
The company is registered with the Registrar of Companies (ROC), Jaipur, under CIN U24290RJ2022PTC080945. Its GSTIN is 08AAWCA8678F1ZU (Rajasthan).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Kanhaiya Lal Vijayvargiya and Prabodh Kumar Govil.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Jaipur, Rajasthan.
As per the financials filed for FY 2025, the company reported a revenue of ₹25.9 Cr, a growth of 7% compared to the previous year. For the same year it recorded a net profit of ₹1.62 Cr (net margin 6.2%) and EBITDA of ₹2.33 Cr (EBITDA margin 9%).
Asle Pharmaceuticals Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-RJ-17-0167681).
Company details
CIN U24290RJ2022PTC080945
Registration Number 080945
Incorporation Date 21 April 2022
ROC Jaipur
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
MSME Classification MSME
Udyam Registration UDYAM-RJ-17-0167681
Recognitions & Rankings of Asle Pharmaceuticals
Contact details
Asle Pharmaceuticals Private Limited's registered office is in Jaipur, Rajasthan.
- Registered AddressSecond Floor House N0.448, Acharya Kriplani Marg Adarsh, Jaipur, Rajasthan, India – 302004
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Asle Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Asle Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Asle Pharmaceuticals Private Limited, buy the company report.
Financials of Asle Pharmaceuticals Private Limited
FY 2024 filings availableAsle Pharmaceuticals Private Limited reported revenue of ₹25.9 Cr (up 7% YoY) for FY 2025.
Revenue · FY 2025
₹25.9 Cr ▲ 7%
Net profit · FY 2025
₹1.62 Cr margin 6.2%
EBITDA · FY 2025
₹2.33 Cr margin 9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 7%
EBITDA CAGR growth
1 year
▲ 168%
Revenue rose 7% in the latest year. EBITDA rose 168% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | ₹2.33 Cr | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | ₹1.62 Cr | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 9% | ||
| Net Profit Margin | 6.2% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Asle Pharmaceuticals Private Limited, buy the company report.
Board of directors of Asle Pharmaceuticals Private Limited
Asle Pharmaceuticals has 3 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kanhaiya Lal Vijayvargiya | Director | 01 Sep 2023 | 3 Years 1 Months | Current |
| Prabodh Kumar Govil | Director | 21 Apr 2022 | 4 Years 6 Months | Current |
| Keshav Joshi | Director | 21 Apr 2022 | 4 Years 6 Months | Current |
Peer comparison
Asle Pharmaceuticals Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Senses Pharmaceuticals Private Limited | ₹26.08 Cr (FY 2025) | 0.0% | Bangalore, Karnataka, India | |||
| Mits Healthcare Private Limited | ₹26.04 Cr (FY 2024) | 19.0% | Muzaffarnagar, Uttar Pradesh, India | |||
| Asle Pharmaceuticals Private Limitedthis company | ₹25.9 Cr (FY 2025) | ₹1.62 Cr | 6.2% | 7.0% | Jaipur, Rajasthan, India | |
| Atopic Laboratories Private Limited | ₹25.88 Cr (FY 2025) | 37.0% | Ahmedabad, Gujarat, India | |||
| Darwin Platform Pharmaceuticals Limited | ₹25.84 Cr (FY 2024) | 0.0% | Mumbai, Maharashtra, India | |||
| Ether Pharmaceuticals Private Limited | ₹25.81 Cr (FY 2025) | 24.0% | Delhi, India |
To see the full peer comparison of Asle Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Asle Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Asle Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Asle Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 08AAWCA8678F1ZU | Rajasthan | Active | 13 Jun 2022 |
To see the full GST registrations and return filing status of Asle Pharmaceuticals Private Limited, buy the company report.
Recent activity
Asle Pharmaceuticals Private Limited has 3 board changes on record since 2022: 3 appointments. The latest: Kanhaiya Lal Vijayvargiya was appointed as Director on 01 Sep 2023.
AGM
Asle Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Asle Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Jaipur.
Appointed
Kanhaiya Lal Vijayvargiya was appointed as Director.
Appointed
Keshav Joshi was appointed as Director.
Appointed
Prabodh Kumar Govil was appointed as Director.
Incorporation
21 Apr 2022
Asle Pharmaceuticals Private Limited was registered on 21 Apr 2022 with Roc Jaipur & aged 4 years 6 months as per MCA records.
Frequently asked questions
Asle Pharmaceuticals is an active private limited company based in Jaipur, Rajasthan, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 April 2022 (4+ years old) and is registered under CIN U24290RJ2022PTC080945.
Asle Pharmaceuticals has 3 current directors:
- Kanhaiya Lal Vijayvargiya - Director
- Prabodh Kumar Govil - Director
- Keshav Joshi - Director
The latest financial statements of Asle Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2023 are in the company report.
The GSTIN of Asle Pharmaceuticals is 08AAWCA8678F1ZU, registered in Rajasthan.
The CIN (Corporate Identification Number) of Asle Pharmaceuticals is U24290RJ2022PTC080945. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Asle Pharmaceuticals was incorporated on 21 April 2022, making it 4+ years old. It is registered with the Registrar of Companies, Jaipur.
The peers of Asle Pharmaceuticals by revenue are Senses Pharmaceuticals Private Limited, Mits Healthcare Private Limited, Atopic Laboratories Private Limited, Darwin Platform Pharmaceuticals Limited, Ether Pharmaceuticals Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading).
Kanhaiya Lal Vijayvargiya was appointed as Director on 01 Sep 2023. Keshav Joshi was appointed as Director on 21 Apr 2022. Prabodh Kumar Govil was appointed as Director on 21 Apr 2022.
Yes, Asle Pharmaceuticals is registered as an MSME under Udyam registration (number: UDYAM-RJ-17-0167681).
The registered office of Asle Pharmaceuticals is at Second Floor House N0.448, Acharya Kriplani Marg Adarsh, Jaipur, Rajasthan, India – 302004.
Asle Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.